QQ客服 官方微博 反馈留言

	Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
	Wu, Yi-Long; Lu, Shun; Cheng, Ying; Zhou, Caicun; Wang, Jie; Mok, Tony; Zhang, Li; Tu, Hai-Yan; Wu, Lin; Feng, Jifeng
	2019
卷号	14期号:5页码:867-875
关键词	Chinese population Nivolumab NSCLC Phase III clinical study
ISSN号	1556-0864
DOI	10.1016/j.jtho.2019.01.006
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6344759
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Wu, Yi-Long,Lu, Shun,Cheng, Ying,et al. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial[J],2019,14(5):867-875.
APA	Wu, Yi-Long.,Lu, Shun.,Cheng, Ying.,Zhou, Caicun.,Wang, Jie.,...&Chang, Jianhua.(2019).Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.,14(5),867-875.
MLA	Wu, Yi-Long,et al."Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial".14.5(2019):867-875.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。